Although our findings from both in vitro studies and the DNCB-induced AD model, along with the observed increase in HSP90 and EPX activity in the leukocytes of the analyzed cohort of AD patients, support the potential use of HSP90 inhibitors in treating individuals with AD, several issues need to be considered when planning future studies. Here, EPX is linked to Alzheimer disease.